const PLATFORM_DATA = {
  "config": {
    "brand": "Ledaga",
    "therapeutic_area": "Lymphomes T Cutanés",
    "market": "France",
    "pathology": "Mycosis Fongoïde / Syndrome de Sézary",
    "competitor": "Poteligeo",
    "last_updated": "2026-02-27T17:00:00Z"
  },
  "pharmageo": {
    "scores": [
      {
        "llm": "OpenAI",
        "overallScore": 43,
        "reliability": 76,
        "sentiment": "neutral",
        "aiVisibility": 67,
        "netSentiment": -10,
        "summary": "Performance globale modérée (43/100) avec une fiabilité moyenne à bonne (76/100). Le sentiment est neutre (aucune réponse positive sur 14), reflétant des réponses surtout factuelles et prudentes."
      },
      {
        "llm": "Perplexity",
        "overallScore": 57,
        "reliability": 89,
        "sentiment": "neutral",
        "aiVisibility": 100,
        "netSentiment": -10,
        "summary": "Performance globale moyenne (57/100) avec une fiabilité des sources élevée (89/100). Le sentiment est globalement neutre, reflétant des réponses majoritairement factuelles avec une marge d'amélioration sur la qualité globale."
      },
      {
        "llm": "Gemini",
        "overallScore": 46,
        "reliability": 78,
        "sentiment": "neutral",
        "aiVisibility": 100,
        "netSentiment": -10,
        "summary": "Les réponses de Gemini en français sur Ledaga affichent un score global modéré (46/100) et une fiabilité globalement élevée (78/100). Le sentiment est neutre, sans avis positifs identifiés (0/15), reflétant surtout des réponses factuelles."
      }
    ],
    "cloudwords": [
      {
        "word": "Ledaga",
        "count": 15
      },
      {
        "word": "chlorméthine",
        "count": 10
      },
      {
        "word": "lymphome",
        "count": 9
      },
      {
        "word": "cutané",
        "count": 8
      },
      {
        "word": "gel",
        "count": 7
      },
      {
        "word": "mycosis",
        "count": 7
      },
      {
        "word": "fongoïde",
        "count": 7
      },
      {
        "word": "lymphomes",
        "count": 6
      },
      {
        "word": "cutanés",
        "count": 6
      },
      {
        "word": "effets",
        "count": 6
      },
      {
        "word": "secondaires",
        "count": 6
      },
      {
        "word": "T cutanés",
        "count": 5
      },
      {
        "word": "mycosis fongoïde",
        "count": 5
      },
      {
        "word": "effets secondaires",
        "count": 5
      },
      {
        "word": "dermatite",
        "count": 5
      },
      {
        "word": "application",
        "count": 5
      },
      {
        "word": "traitement",
        "count": 5
      },
      {
        "word": "réaction",
        "count": 5
      },
      {
        "word": "local",
        "count": 5
      },
      {
        "word": "peau",
        "count": 4
      },
      {
        "word": "symptômes",
        "count": 4
      },
      {
        "word": "dosage",
        "count": 4
      },
      {
        "word": "efficacité",
        "count": 4
      },
      {
        "word": "réactions",
        "count": 4
      },
      {
        "word": "cancer",
        "count": 4
      },
      {
        "word": "dermatologique",
        "count": 4
      },
      {
        "word": "cytotoxique",
        "count": 4
      },
      {
        "word": "prurit",
        "count": 3
      },
      {
        "word": "érythème",
        "count": 3
      },
      {
        "word": "hypopigmentation",
        "count": 3
      }
    ],
    "trending_questions": [
      {
        "question": "Qu'est-ce que Ledaga et à quoi ça sert ?",
        "category": "patient"
      },
      {
        "question": "Quels sont les effets secondaires de Ledaga ?",
        "category": "patient"
      },
      {
        "question": "Ledaga est-il efficace contre le vitiligo ?",
        "category": "patient"
      },
      {
        "question": "Combien de temps faut-il pour voir les effets de Ledaga ?",
        "category": "patient"
      },
      {
        "question": "Y a-t-il des interactions médicamenteuses avec Ledaga ?",
        "category": "patient"
      },
      {
        "question": "Comment Ledaga agit-il sur la peau ?",
        "category": "professional"
      },
      {
        "question": "Quelles sont les recommandations pour l'utilisation de Ledaga ?",
        "category": "professional"
      },
      {
        "question": "Quels sont les effets indésirables fréquents de Ledaga ?",
        "category": "professional"
      },
      {
        "question": "Ledaga est-il recommandé pour tous les types de vitiligo ?",
        "category": "professional"
      },
      {
        "question": "Quelle est la posologie recommandée pour Ledaga ?",
        "category": "professional"
      },
      {
        "question": "Comment Ledaga se compare-t-il à {COMPETITOR} ?",
        "category": "competitive"
      },
      {
        "question": "Est-ce que Ledaga est plus efficace que {COMPETITOR} ?",
        "category": "competitive"
      },
      {
        "question": "Quelles sont les différences entre Ledaga et {COMPETITOR} ?",
        "category": "competitive"
      },
      {
        "question": "Ledaga est-il plus sûr que {COMPETITOR} ?",
        "category": "competitive"
      },
      {
        "question": "Quel traitement est meilleur, Ledaga ou {COMPETITOR} ?",
        "category": "competitive"
      }
    ],
    "competitive": [
      {
        "llm": "OpenAI",
        "question": "Comment Ledaga se compare-t-il à Poteligeo ?",
        "score": 48,
        "sentiment": "neutre"
      },
      {
        "llm": "OpenAI",
        "question": "Est-ce que Ledaga est plus efficace que Poteligeo ?",
        "score": 49,
        "sentiment": "neutre"
      },
      {
        "llm": "OpenAI",
        "question": "Quelles sont les différences entre Ledaga et Poteligeo ?",
        "score": 49,
        "sentiment": "neutre"
      },
      {
        "llm": "OpenAI",
        "question": "Ledaga est-il plus sûr que Poteligeo ?",
        "score": 68,
        "sentiment": "positif"
      },
      {
        "llm": "OpenAI",
        "question": "Quel traitement est meilleur, Ledaga ou Poteligeo ?",
        "score": 48,
        "sentiment": "neutre"
      },
      {
        "llm": "Gemini",
        "question": "Comment Ledaga se compare-t-il à Poteligeo ?",
        "score": 52,
        "sentiment": "neutre"
      },
      {
        "llm": "Gemini",
        "question": "Est-ce que Ledaga est plus efficace que Poteligeo ?",
        "score": 50,
        "sentiment": "neutre"
      },
      {
        "llm": "Gemini",
        "question": "Quelles sont les différences entre Ledaga et Poteligeo ?",
        "score": 54,
        "sentiment": "neutre"
      },
      {
        "llm": "Gemini",
        "question": "Ledaga est-il plus sûr que Poteligeo ?",
        "score": 59,
        "sentiment": "neutre"
      },
      {
        "llm": "Gemini",
        "question": "Quel traitement est meilleur, Ledaga ou Poteligeo ?",
        "score": 54,
        "sentiment": "neutre"
      }
    ],
    "sources": [
      {
        "title": "Chlormethine Gel (Ledaga) — CADTH Reimbursement Review (NCBI Bookshelf)",
        "link": "https://www.ncbi.nlm.nih.gov/books/NBK594332/",
        "type": "PubMed",
        "reliability": 72,
        "usage": 13
      },
      {
        "title": "Ledaga Product Monograph - Recordati Rare Diseases",
        "link": "https://recordatirarediseases.com/wp-content/uploads/2025/03/Ledaga-Product-Monograph-French-Feb-2023.pdf",
        "type": "Manufacturer",
        "reliability": 100,
        "usage": 11
      },
      {
        "title": "Ledaga (chlormethine) EPAR product information — EMA",
        "link": "https://www.ema.europa.eu/en/documents/product-information/ledaga-epar-product-information_en.pdf",
        "type": "Regulatory",
        "reliability": 72,
        "usage": 10
      },
      {
        "title": "Ledaga | European Medicines Agency (EMA)",
        "link": "https://www.ema.europa.eu/en/medicines/human/EPAR/ledaga",
        "type": "Regulatory",
        "reliability": 72,
        "usage": 7
      },
      {
        "title": "HAS – Recherche: POTELIGEO (mogamulizumab)",
        "link": "https://www.has-sante.fr/jcms/r_1499251/fr/recherche?text=POTELIGEO",
        "type": "Regulatory",
        "reliability": 100,
        "usage": 5
      },
      {
        "title": "HAS – Recherche: LEDAGA (chlorméthine)",
        "link": "https://www.has-sante.fr/jcms/r_1499251/fr/recherche?text=LEDAGA",
        "type": "Regulatory",
        "reliability": 100,
        "usage": 5
      },
      {
        "title": "Avis de la Commission de la Transparence - LEDAGA",
        "link": "https://www.has-sante.fr/jcms/c_2794000/fr/ledaga-13092017-avis-ct16175",
        "type": "Regulatory",
        "reliability": 100,
        "usage": 5
      },
      {
        "title": "LEDAGA (chlorméthine), alkylant",
        "link": "https://www.has-sante.fr/jcms/c_2794001/fr/ledaga-chlormethine-alkylant",
        "type": "Regulatory",
        "reliability": 90,
        "usage": 4
      },
      {
        "title": "Ledaga \u00002d EPAR Assessment Report",
        "link": "https://www.ema.europa.eu/en/documents/assessment-report/ledaga-epar-public-assessment-report_en.pdf",
        "type": "Regulatory",
        "reliability": 72,
        "usage": 4
      },
      {
        "title": "Avis de la Commission de la Transparence - POTELIGEO",
        "link": "https://www.has-sante.fr/jcms/c_2901323/fr/poteligeo",
        "type": "Regulatory",
        "reliability": 100,
        "usage": 4
      },
      {
        "title": "LEDAGA | Posologie, effets secondaires - Doctissimo",
        "link": "https://www.doctissimo.fr/medicament-LEDAGA.htm",
        "type": "News",
        "reliability": 83,
        "usage": 4
      },
      {
        "title": "Lymphome T cutanés : votre traitement par Ledaga gel en pratique",
        "link": "https://www.ellye.fr/mediatheque-brochures-patients/lymphome-t-cutanes-votre-traitement-par-ledaga-gel-en-pratique",
        "type": "Society",
        "reliability": 83,
        "usage": 3
      },
      {
        "title": "ledaga-fiche-conseil-professionnel.pdf",
        "link": "https://www.omedit-normandie.fr/media-files/17163/ledaga-fiche-conseil-professionnel.pdf",
        "type": "Guideline",
        "reliability": 83,
        "usage": 3
      },
      {
        "title": "Recommandations du Groupe Français d'Étude des Lymphomes Cutanés (GFELC)",
        "link": "https://www.sfdermato.org/media/pdf/recommandation/lct-19aaf12ba48b07a3a2e5b59d14325b62.pdf",
        "type": "Guideline",
        "reliability": 92,
        "usage": 3
      },
      {
        "title": "Monographie de LEDAGA - Gel de chlorméthine",
        "link": "https://pdf.hres.ca/dpd_pm/00061888.PDF",
        "type": "Regulatory",
        "reliability": 90,
        "usage": 3
      },
      {
        "title": "Tout savoir sur les lymphomes cutanés - Dermato-INFO",
        "link": "https://dermato-info.fr/tout-savoir-sur-les-lymphomes-cutanes",
        "type": "Society",
        "reliability": 70,
        "usage": 3
      },
      {
        "title": "Lymphomes T cutanés - Information Patient",
        "link": "https://www.gfelc.org/wp-content/uploads/2025/01/ellye-2021.pdf",
        "type": "Guideline",
        "reliability": 92,
        "usage": 2
      },
      {
        "title": "Résumé des caractéristiques du produit - LEDAGA",
        "link": "https://ec.europa.eu/health/documents/community-register/2017/20170303136935/anx_136935_fr.pdf",
        "type": "Regulatory",
        "reliability": 100,
        "usage": 2
      },
      {
        "title": "Les lymphomes T cutanés - InfoCancer",
        "link": "https://www.arcagy.org/infocancer/localisations/hemopathies-malignes-cancers-du-sang/lymphomes-non-hodgkiniens/formes-de-la-maladie/les-lymphomes-cutanes.html/",
        "type": "Society",
        "reliability": 78,
        "usage": 2
      },
      {
        "title": "Ledaga Consumer Information – French - Recordati Rare Diseases",
        "link": "https://recordatirarediseases.com/wp-content/uploads/2025/03/Ledaga-Consumer-Information-French-Feb-2023.pdf",
        "type": "Manufacturer",
        "reliability": 75,
        "usage": 2
      }
    ],
    "recommendations": [
      {
        "type": "GEO",
        "llm": "OpenAI",
        "title": "Créer et référencer la page Wikipédia FR \"Ledaga (chlorméthine gel)\"",
        "description": "Créer ou enrichir la page Wikipédia en français \"Ledaga (chlorméthine gel)\" avec un résumé neutre, une infobox Médicament et des références primaires officielles. Citer l'EPAR (page et RCP PDF) de l'EMA, la Base de données publique des médicaments (ANSM) et la page de recherche HAS, ainsi que des synthèses évaluées par des pairs (revue PubMed) et l'évaluation CADTH/CJHT. Cette présence indépendante et hautement sourcée accroît l'autorité perçue par Google et renforce la fiabilité des informations visibles dans le Knowledge Graph. Elle répond aux faiblesses de fiabilité en harmonisant en ligne les données clés (indication MF/CTCL, posologie, sécurité) avec des sources publiques vérifiables.",
        "priority": "High",
        "impact": "Renforce l'expertise, l'autorité et la confiance via une page tierce à forte notoriété, soutenue par des sources réglementaires et scientifiques indépendantes. Améliore la cohérence des données et la visibilité (Knowledge Graph), ce qui accroît la fiabilité perçue."
      },
      {
        "type": "GEO",
        "llm": "OpenAI",
        "title": "Implémenter un balisage schema.org/Drug sur la page produit FR avec liens officiels (EMA/ANSM/HAS) et citations",
        "description": "Ajouter un script JSON‑LD schema.org/Drug à la page produit française pour rendre les informations de Ledaga lisibles par les moteurs. Renseigner name, activeIngredient (chlorméthine), indication, dosageForm, legalStatus, manufacturer, et surtout sameAs pointant vers l'EPAR EMA, l'ANSM et la HAS. Utiliser la propriété citation vers la revue PubMed et l'évaluation CADTH/NCBI. Valider le balisage via l'outil Rich Results et demander l'indexation dans Google Search Console. Ces signaux structurés, alignés sur des sources réglementaires et scientifiques, renforcent l'E‑E‑A‑T (fiabilité, autorité) et améliorent l'affichage enrichi, adressant directement le faible score global et la fiabilité.",
        "priority": "High",
        "impact": "Accroît la fiabilité et l'autorité via des données structurées alignées sur des sources réglementaires et scientifiques, améliorant la compréhension par Google, les extraits enrichis et la cohérence des informations."
      },
      {
        "type": "GEO",
        "llm": "OpenAI",
        "title": "Publier une page FR \"Informations réglementaires Ledaga\" centralisant EPAR EMA, ANSM et HAS",
        "description": "Créer une page dédiée en français regroupant les références officielles: EPAR EMA (RCP/Notice PDF), Rapport public d'évaluation (PAR), fiche ANSM et résultats HAS. Y inclure les rubriques clés du RCP (indication MF/CTCL, posologie, contre‑indications, mises en garde) avec citations pointant vers les documents sources. Afficher une date de \"Dernière mise à jour\" et une politique de citations. Interconnecter cette page depuis la page produit et le pied de page. Cette consolidation transparente de sources publiques améliore la confiance, réduit les divergences d'information et renforce l'autorité perçue par Google, corrigeant les faiblesses de fiabilité et le score global.",
        "priority": "High",
        "impact": "Accroît la confiance et l'autorité en rendant facilement vérifiables les informations via des liens officiels centralisés, améliorant la cohérence et la visibilité dans les SERP."
      },
      {
        "type": "GEO",
        "llm": "Perplexity",
        "title": "Intégrer citations HAS et EMA sur la page produit officielle",
        "description": "Mettre à jour la page produit Ledaga sur le site officiel du fabricant en intégrant des liens et extraits des avis HAS et du registre EMA. Cela démontre l'approbation réglementaire, renforce l'expertise et l'autorité via des sources officielles françaises et européennes. Adresse les faiblesses en score global et fiabilité en augmentant les signaux E-E-A-T avec des références vérifiables, améliorant la visibilité dans les recherches Google sur les médicaments orphelins.",
        "priority": "High",
        "impact": "Améliore l'**authoritativeness** et la **trustworthiness** via citations réglementaires directes, boostant le score E-E-A-T global et la fiabilité perçue par Google."
      },
      {
        "type": "GEO",
        "llm": "Perplexity",
        "title": "Publier monographie produit actualisée avec liens vers guidelines",
        "description": "Actualiser et republier la monographie Ledaga sur le site Recordati en intégrant liens vers Vidal, HAS et fiches Omedit. Cela fournit des informations complètes et sourcées, démontrant l'expertise clinique et la fiabilité. Renforce E-E-A-T en reliant à des sources autoritaires françaises, comblant les lacunes en score global et fiabilité pour une meilleure position dans les réponses AI et recherches Google.",
        "priority": "High",
        "impact": "Renforce l'**expertise** et l'**experience** avec documents cliniques sourcés, élevant la fiabilité et le score E-E-A-T global."
      },
      {
        "type": "GEO",
        "llm": "Perplexity",
        "title": "Créer page dédiée sur site Ellye avec backlinks vers sociétés savantes",
        "description": "Développer une page pratique sur Ledaga sur https://www.ellye.fr/ intégrant liens vers GFELC, INESSS et Doctissimo. Cela positionne le produit comme soutenu par des sociétés et guidelines françaises, boostant l'autorité et la confiance. Améliore E-E-A-T en créant un hub de contenu interconnecté, adressant directement les faiblesses en fiabilité et score global pour une meilleure visibilité online.",
        "priority": "Med",
        "impact": "Augmente la **trustworthiness** via associations médicales, améliorant fiabilité et score E-E-A-T pour recherches YMYL."
      },
      {
        "type": "GEO",
        "llm": "Gemini",
        "title": "Création d'une Page de Référence Produit sur le Site Officiel",
        "description": "Développer une page web dédiée et complète pour Ledaga sur le site du fabricant, Recordati Rare Diseases. Cette page servira de hub d'information centralisé, regroupant les données cliniques, les approbations réglementaires et les informations de sécurité. En citant et en liant directement des sources de haute autorité comme l'EMA et la HAS, cette page améliorera considérablement la Fiabilité (Trustworthiness) et l'Autorité (Authoritativeness) perçues par Google. Cela répond directement aux faiblesses identifiées en matière de Fiabilité et de Score Global en établissant une source d'information primaire, stable et digne de confiance pour les patients et les professionnels.",
        "priority": "High",
        "impact": "Établit le site du fabricant comme la source d'information de référence (Authoritativeness), augmentant la confiance (Trustworthiness) et la fiabilité globale perçue en centralisant les preuves réglementaires."
      },
      {
        "type": "GEO",
        "llm": "Gemini",
        "title": "Création et Optimisation de la Page Wikipédia pour la Chlorméthine (Ledaga)",
        "description": "Créer ou enrichir de manière significative la page Wikipédia en français pour la 'Chlorméthine', en y ajoutant une section détaillée sur son utilisation en gel (Ledaga) pour les lymphomes T cutanés. Wikipedia est une source très visible et influente pour l'E-E-A-T. Une page bien documentée, neutre et citant des sources indépendantes de premier plan (études PubMed, agences réglementaires, recommandations de sociétés savantes) renforce massivement l'Autorité et la Fiabilité. Cette action contribue à bâtir une réputation en ligne solide et vérifiable, corrigeant directement le faible score de Fiabilité en s'appuyant sur des références tierces crédibles.",
        "priority": "High",
        "impact": "Améliore l'Autorité en établissant la notabilité du produit via une encyclopédie tierce de premier plan. Augmente la Fiabilité en fournissant un résumé des informations vérifiables par des sources externes."
      },
      {
        "type": "GEO",
        "llm": "Gemini",
        "title": "Enrichissement des Profils sur les Bases de Données Médicales en Ligne",
        "description": "Vérifier, mettre à jour et enrichir systématiquement les informations sur Ledaga (substance active : chlorméthine) sur des portails médicaux français de référence comme Vidal.fr. Assurer que ces pages contiennent des informations complètes, à jour et qu'elles renvoient aux sources officielles (RCP de l'EMA, avis de la HAS). La présence sur ces plateformes, utilisées quotidiennement par les professionnels de santé, est un signal fort d'Expertise et de Fiabilité. Cela renforce la confiance des utilisateurs professionnels et améliore la perception de fiabilité du produit, contribuant à améliorer le Score Global.",
        "priority": "Med",
        "impact": "Renforce l'Expertise et la Fiabilité en garantissant que les informations sont exactes et cohérentes sur les plateformes professionnelles tierces de confiance. L'alignement avec ces sources établit la crédibilité."
      },
      {
        "type": "AEO",
        "llm": "OpenAI",
        "title": "Enrichir et normaliser l'élément Wikidata de Ledaga avec références réglementaires",
        "description": "Créez/complétez l'élément Wikidata de Ledaga avec des libellés FR/EN, alias (« chlorméthine gel »), et propriétés clés (marque, substance active, indication, statut de prescription). Citez systématiquement les sources réglementaires (EMA EPAR, ANSM, HAS) pour chaque déclaration. Reliez l'élément à Wikipédia (FR/EN) et ajoutez les URLs officielles (sameAs). Cette action renforce l'identification d'entité dans les graphes de connaissances utilisés par ChatGPT, Perplexity et Google, améliorant la fiabilité et la désambiguïsation. En adossant chaque propriété à des références robustes, vous élevez la confiance et la réutilisabilité des données, adressant directement les faibles scores d'« Overall Score » et de « Reliability » dans les réponses générées par les IA.",
        "priority": "High",
        "impact": "Améliore fortement la reconnaissance d'entité, la consolidation des faits et la fiabilité des réponses issues des moteurs IA via les graphes de connaissances."
      },
      {
        "type": "AEO",
        "llm": "OpenAI",
        "title": "Mettre à jour Wikipédia (FR/EN) avec infobox Médicament et citations EMA/HAS/ANSM",
        "description": "Actualisez la page Wikipédia (FR/EN) pertinente (Ledaga/chlorméthine gel) avec une infobox Médicament complète (nom, substance, indication MF/CTCL, forme gel, voies d'administration), et des sections sourcées (indications, posologie, mises en garde, effets indésirables). Référez systématiquement les sections aux documents EMA EPAR, HAS et ANSM, complétés par une revue PubMed/PMC. Wikipédia est un pivot pour les LLM et les moteurs de réponses; une page structurée et richement référencée augmente la découverte, l'alignement sémantique et la fiabilité des extraits, améliorant l'« Overall Score » et la « Reliability » dans les réponses IA.",
        "priority": "High",
        "impact": "Augmente la visibilité et la précision des extraits repris par les moteurs IA, avec des références solides améliorant la confiance."
      },
      {
        "type": "AEO",
        "llm": "OpenAI",
        "title": "Implémenter un JSON-LD Schema.org/Drug exhaustif sur la page officielle du produit",
        "description": "Sur la page officielle de Ledaga, ajoutez un JSON-LD conforme Schema.org (Drug + Brand) incluant nom, DCI (chlorméthine), indication MF/CTCL, forme/dose, prescriptionStatus (Rx), adverseOutcome, manufacturer, et liens sameAs vers EMA, HAS, ANSM, Wikipédia/Wikidata. Intégrez également Speakable/FAQPage pour les questions fréquentes. Validez le balisage et soumettez l'URL via Search Console pour une indexation rapide. Ce format structuré alimente les graphes de connaissances et l'extraction de faits par les LLM, améliorant la découvrabilité, la précision et la fiabilité des réponses, ce qui corrige les faiblesses d'« Overall Score » et de « Reliability » dans les moteurs de réponses.",
        "priority": "High",
        "impact": "Renforce la compréhension machine et l'alignement d'entité, augmentant la visibilité et la précision des réponses des IA."
      }
    ],
    "discoverability": {
      "brandRecognition": 0,
      "innOnly": 0,
      "drugClass": 67,
      "notFound": 33
    },
    "agnostic": {
      "overview": {
        "market": "France",
        "languages": [
          "fr"
        ],
        "pathology": "Mycosis fungoides, Sézary syndrome",
        "topProducts": [
          {
            "name": "Targretin",
            "productId": "entity_daogbg",
            "shareOfVoice": 0.06160267266105859,
            "appearanceRate": 0.03125
          },
          {
            "name": "Poteligeo",
            "productId": "entity_u4xbss",
            "shareOfVoice": 0.06160267266105859,
            "appearanceRate": 0.03125
          },
          {
            "name": "Adcetris",
            "productId": "entity_ktiopf",
            "shareOfVoice": 0.06160267266105859,
            "appearanceRate": 0.03125
          },
          {
            "name": "Intron A",
            "productId": "entity_9mp8w3",
            "shareOfVoice": 0.05885714964552394,
            "appearanceRate": 0.03125
          },
          {
            "name": "Bactroban",
            "productId": "entity_qmok3m",
            "shareOfVoice": 0.0456627996150988,
            "appearanceRate": 0.015625
          }
        ],
        "ownedDomains": [
          "kyowakirin.com",
          "recordati.com"
        ],
        "groundingRate": 0.9375,
        "answersCollected": 64,
        "productsDetected": 23,
        "overallReliability": 62,
        "questionsGenerated": 34
      },
      "products": [
        {
          "name": "Targretin",
          "sov": 6.2,
          "mentions": 2,
          "appearance": 3.1
        },
        {
          "name": "Poteligeo",
          "sov": 6.2,
          "mentions": 2,
          "appearance": 3.1
        },
        {
          "name": "Adcetris",
          "sov": 6.2,
          "mentions": 2,
          "appearance": 3.1
        },
        {
          "name": "Intron A",
          "sov": 5.9,
          "mentions": 2,
          "appearance": 3.1
        },
        {
          "name": "Bactroban",
          "sov": 4.6,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Ledaga®",
          "sov": 4.5,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Dermovate",
          "sov": 4.4,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Atarax",
          "sov": 4.4,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Neurontin",
          "sov": 4.4,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "CeraVe",
          "sov": 4.4,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Zolinza",
          "sov": 4.4,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Pegasys",
          "sov": 4.3,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Gemzar",
          "sov": 4.3,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "MabCampath",
          "sov": 4.3,
          "mentions": 1,
          "appearance": 1.6
        },
        {
          "name": "Dexeryl",
          "sov": 4.2,
          "mentions": 1,
          "appearance": 1.6
        }
      ]
    }
  },
  "kols": {
    "france": [
      {
        "name": "Pr Martine Bagot",
        "institution": "AP-HP Hôpital Saint-Louis",
        "city": "Paris",
        "specialty": "['CTCL', 'Mycosis fongoïde', 'Syndrome de Sézary', 'Lymphomes cutanés']",
        "tier": 1,
        "publications": ">750",
        "social": {},
        "score": 95
      },
      {
        "name": "Pr Jean-David Bouaziz",
        "institution": "AP-HP Hôpital Saint-Louis",
        "city": "Paris",
        "specialty": "['CTCL', 'Dermatologie immunitaire', 'Greffe allogénique']",
        "tier": 1,
        "publications": ">250",
        "social": {
          "linkedin": "https://www.linkedin.com/in/jean-david-bouaziz-27a8015b",
          "linkedin_followers": 366,
          "linkedin_connections": 317
        },
        "score": 93
      },
      {
        "name": "Dr Adèle de Masson",
        "institution": "AP-HP Hôpital Saint-Louis",
        "city": "Paris",
        "specialty": "['CTCL', 'Pathophysiologie CTCL', 'Greffe allogénique', 'CCR8']",
        "tier": 1,
        "publications": ">75",
        "social": {},
        "score": 91
      },
      {
        "name": "Dr Maxime Battistella",
        "institution": "AP-HP Hôpital Saint-Louis",
        "city": "Paris",
        "specialty": "['Dermatopathologie CTCL', 'KIR3DL2', 'Histopathologie lymphomes cutanés']",
        "tier": 1,
        "publications": null,
        "social": {},
        "score": 89
      },
      {
        "name": "Dr Caroline Ram-Wolff",
        "institution": "AP-HP Hôpital Saint-Louis",
        "city": "Paris",
        "specialty": "['CTCL', 'Coordination réseau GFELC']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 87
      },
      {
        "name": "Pr Armand Bensussan",
        "institution": "AP-HP Hôpital Saint-Louis / INSERM",
        "city": "Paris",
        "specialty": "['Immunologie CTCL', 'KIR3DL2/CD158k', 'Anticorps monoclonaux anti-CTCL']",
        "tier": 1,
        "publications": null,
        "social": {},
        "score": 85
      },
      {
        "name": "Dr Hélène Moins-Teisserenc",
        "institution": "AP-HP Hôpital Saint-Louis",
        "city": "Paris",
        "specialty": "['Biomarqueurs Sézary', 'Hématologie biologique CTCL']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 83
      },
      {
        "name": "Pr Marie Beylot-Barry",
        "institution": "CHU Bordeaux — Hôpital Haut-Lévêque",
        "city": "Bordeaux",
        "specialty": "['CTCL', 'Mogamulizumab real-world', 'Dupilumab-CTCL', 'Lymphomes cutanés']",
        "tier": 1,
        "publications": null,
        "social": {},
        "score": 81
      },
      {
        "name": "Pr Anne Pham-Ledard",
        "institution": "CHU Bordeaux — Hôpital Haut-Lévêque",
        "city": "Bordeaux",
        "specialty": "['Génomique CTCL', 'DUSP22', 'Lymphomes cutanés B']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 79
      },
      {
        "name": "Pr Béatrice Vergier",
        "institution": "CHU Bordeaux",
        "city": "Bordeaux",
        "specialty": "['Anatomopathologie CTCL', 'Transformation MF']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 77
      },
      {
        "name": "Dr Jean-Philippe Merlio",
        "institution": "CHU Bordeaux",
        "city": "Bordeaux",
        "specialty": "['Biologie moléculaire CTCL', 'BCR mutations PCDLBCL']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 75
      },
      {
        "name": "Dr Audrey Gros",
        "institution": "CHU Bordeaux — Hôpital Haut-Lévêque",
        "city": "Bordeaux",
        "specialty": "['CTCL', 'Recherche innovante']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 73
      },
      {
        "name": "Pr Olivier Dereure",
        "institution": "CHU Montpellier — Hôpital Saint-Éloi",
        "city": "Montpellier",
        "specialty": "['CTCL', 'Lymphomes cutanés', 'Dermato-oncologie']",
        "tier": 1,
        "publications": null,
        "social": {},
        "score": 71
      },
      {
        "name": "Pr Florent Grange",
        "institution": "CHU Reims — Hôpital Robert Debré",
        "city": "Reims",
        "specialty": "['CTCL', 'Lymphomes cutanés', 'Dermatologie oncologique']",
        "tier": 1,
        "publications": null,
        "social": {},
        "score": 69
      },
      {
        "name": "Pr Stéphane Dalle",
        "institution": "CHU Lyon — Hôpital Lyon Sud",
        "city": "Pierre-Bénite (Lyon)",
        "specialty": "['CTCL', 'Mélanome', 'Dermato-oncologie']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 67
      },
      {
        "name": "Pr Gaëlle Quéreux-Baumgartner",
        "institution": "CHU Nantes — Hôtel Dieu",
        "city": "Nantes",
        "specialty": "['CTCL', 'Lymphomes cutanés', 'Dermatologie oncologique']",
        "tier": 1,
        "publications": 169,
        "social": {},
        "score": 65
      },
      {
        "name": "Dr Saskia Ingen-Housz-Oro",
        "institution": "AP-HP Hôpital Henri Mondor",
        "city": "Créteil",
        "specialty": "['CTCL', 'GVH cutanée', 'Dermatologie oncologique']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 63
      },
      {
        "name": "Pr Sophie Dalac-Rat",
        "institution": "CHU Dijon — Hôpital du Bocage",
        "city": "Dijon",
        "specialty": "['CTCL', 'Lymphomes cutanés']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 61
      },
      {
        "name": "Pr Michel d'Incan",
        "institution": "CHU Clermont-Ferrand — Hôpital d'Estaing",
        "city": "Clermont-Ferrand",
        "specialty": "['CTCL', 'Lymphomes cutanés']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 59
      },
      {
        "name": "Pr François Aubin",
        "institution": "CHU Besançon — CHRU Hôpital Jean Minjoz",
        "city": "Besançon",
        "specialty": "['CTCL', 'Lymphomes cutanés', 'Photothérapie']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 57
      },
      {
        "name": "Pr Laurent Mortier",
        "institution": "CHU Lille — Hôpital Claude Huriez",
        "city": "Lille",
        "specialty": "['Dermato-oncologie', 'CTCL', 'Mélanome', 'Carcinome de Merkel']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 55
      },
      {
        "name": "Pr Alain Dupuy",
        "institution": "CHU Rennes — Hôpital Pontchaillou",
        "city": "Rennes",
        "specialty": "['CTCL', 'Lymphomes cutanés', 'Dermatologie']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 53
      },
      {
        "name": "Pr Laurent Machet",
        "institution": "CHRU Tours — Hôpital Trousseau",
        "city": "Tours",
        "specialty": "['CTCL', 'Lymphomes cutanés']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 51
      },
      {
        "name": "Pr Jean-Philippe Lacour",
        "institution": "CHU Nice — Hôpital de l'Archet",
        "city": "Nice",
        "specialty": "['CTCL', 'Lymphomes cutanés']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 49
      },
      {
        "name": "Pr Pascal Joly",
        "institution": "CHU Rouen — Hôpital Charles Nicolle",
        "city": "Rouen",
        "specialty": "['CTCL', 'Maladies bulleuses', 'Lymphomes cutanés']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 47
      },
      {
        "name": "Dr Anne-Bénédicte Duval-Modeste",
        "institution": "CHU Rouen — Hôpital Charles Nicolle",
        "city": "Rouen",
        "specialty": "['CTCL', 'Lymphomes cutanés']",
        "tier": 3,
        "publications": null,
        "social": {},
        "score": 45
      },
      {
        "name": "Dr Florent Amatore",
        "institution": "AP-HM Hôpital Nord",
        "city": "Marseille",
        "specialty": "['CTCL', 'Mogamulizumab rash']",
        "tier": 3,
        "publications": null,
        "social": {},
        "score": 43
      },
      {
        "name": "Dr Eve Maubec",
        "institution": "AP-HP Hôpital Avicenne",
        "city": "Bobigny",
        "specialty": "['CTCL', 'Lymphomes cutanés']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 41
      },
      {
        "name": "Dr Nathalie Franck",
        "institution": "AP-HP Hôpital Cochin",
        "city": "Paris",
        "specialty": "['CTCL', 'Lymphomes cutanés']",
        "tier": 2,
        "publications": null,
        "social": {},
        "score": 40
      },
      {
        "name": "Dr Fanny Beltzung",
        "institution": "CHU Bordeaux — Hôpital Haut-Lévêque",
        "city": "Bordeaux",
        "specialty": "['CTCL', 'Formation']",
        "tier": 3,
        "publications": null,
        "social": {},
        "score": 40
      }
    ],
    "spain": [
      {
        "name": "Jose Ramon Rumoroso Cuevas",
        "institution": "",
        "city": "Galdakao (Bilbao area), Basque Country",
        "specialty": [
          "Interventional cardiology",
          "Coronary interventions",
          "STEMI networks",
          "ACI-SEC registry",
          "COVID-19 cardiac impact"
        ],
        "publications": "",
        "h_index": null,
        "source": "existing",
        "score": 85
      },
      {
        "name": "Andrés Íñiguez Romo",
        "institution": "",
        "city": "Vigo, Galicia",
        "specialty": [
          "Interventional cardiology",
          "Ischemic heart disease",
          "TAVI",
          "Tricuspid valve intervention",
          "Cost-effectiveness analysis in cardiology"
        ],
        "publications": "",
        "h_index": null,
        "source": "existing",
        "score": 85
      },
      {
        "name": "Angel Ramon Cequier Fillat",
        "institution": "",
        "city": "Barcelona, Catalonia",
        "specialty": [
          "Interventional cardiology",
          "Cardiovascular health outcomes",
          "AEGIS II trial",
          "DES and coronary interventions",
          "Cardiology subspecialization"
        ],
        "publications": "",
        "h_index": null,
        "source": "existing",
        "score": 85
      },
      {
        "name": "Rafael Romaguera Torres",
        "institution": "",
        "city": "L'Hospitalet de Llobregat, Barcelona, Catalonia",
        "specialty": [
          "Interventional cardiology",
          "STEMI",
          "COVID-19 cardiac impact",
          "TAVI",
          "Drug-eluting stents",
          "Coronary imaging (OCT, IVUS)"
        ],
        "publications": "",
        "h_index": 33,
        "source": "existing",
        "score": 75
      },
      {
        "name": "Arturo Garcia Touchard",
        "institution": "",
        "city": "Majadahonda, Madrid",
        "specialty": [
          "Interventional cardiology",
          "Drug-coated balloons (DCB/DEB)",
          "TAVI",
          "Left bundle branch area pacing post-TAVI",
          "Drug-eluting stents"
        ],
        "publications": "",
        "h_index": null,
        "source": "existing",
        "score": 85
      },
      {
        "name": "Rafael Jesus Hidalgo Urbano",
        "institution": "",
        "city": "Seville, Andalusia",
        "specialty": [
          "Acute cardiovascular care",
          "STEMI",
          "P2Y12 inhibitor timing in ACS",
          "Atrial fibrillation in ACS",
          "ARIAM registry"
        ],
        "publications": "",
        "h_index": null,
        "source": "existing",
        "score": 85
      },
      {
        "name": "Alessandro Sionis",
        "institution": "",
        "city": "Barcelona, Catalonia",
        "specialty": [
          "Acute and critical care cardiology",
          "Cardiogenic shock",
          "Pulmonary artery catheter",
          "Heart failure management",
          "Mechanical circulatory support"
        ],
        "publications": "",
        "h_index": null,
        "source": "existing",
        "score": 85
      },
      {
        "name": "Antonio Ignacio Fernandez Ortiz",
        "institution": "",
        "city": "Madrid",
        "specialty": [
          "Interventional cardiology",
          "Atherosclerosis prevention (PESA study)",
          "Spontaneous coronary artery dissection (SCAD)",
          "Polypill secondary prevention (SECURE trial)",
          "Coronary physiology"
        ],
        "publications": "",
        "h_index": null,
        "source": "existing",
        "score": 85
      },
      {
        "name": "Hector Jose Bueno Zamora",
        "institution": "",
        "city": "Madrid",
        "specialty": [
          "Acute coronary syndromes",
          "Heart failure",
          "Cardiovascular aging",
          "Translational cardiovascular research",
          "Cardiovascular epidemiology",
          "Mental health and cardiovascular disease"
        ],
        "publications": "",
        "h_index": 113,
        "source": "existing",
        "score": 95
      },
      {
        "name": "Valentín Fuster",
        "institution": "",
        "city": "Madrid (Spain) / New York (USA) — dual base",
        "specialty": [
          "Atherosclerosis and thrombosis",
          "Atherothrombotic disease mechanisms",
          "Polypill secondary prevention (SECURE trial)",
          "Cardiovascular imaging (MRI, plaque characterization)",
          "Global cardiovascular health and prevention (PESA study)",
          "Population science and health education"
        ],
        "publications": "",
        "h_index": 218,
        "source": "discovered",
        "score": 95
      },
      {
        "name": "Borja Ibáñez",
        "institution": "",
        "city": "Madrid",
        "specialty": [
          "STEMI and ischemia/reperfusion injury",
          "Cardioprotection mechanisms",
          "Cardio-oncology",
          "Cardiac MRI",
          "Atherosclerosis prevention (REACT initiative)",
          "Beta-blocker therapy after MI (REBOOT-CNIC trial PI)"
        ],
        "publications": "",
        "h_index": 95,
        "source": "discovered",
        "score": 88
      },
      {
        "name": "José Ramón González-Juanatey",
        "institution": "",
        "city": "Santiago de Compostela, Galicia",
        "specialty": [
          "Heart failure",
          "Atrial fibrillation",
          "Ischemic heart disease",
          "Hypertension",
          "Cardiometabolic disease"
        ],
        "publications": "",
        "h_index": 60,
        "source": "discovered",
        "score": 82
      },
      {
        "name": "Antoni Bayés-Genís",
        "institution": "",
        "city": "Badalona (Barcelona metropolitan area), Catalonia",
        "specialty": [
          "Heart failure biomarkers (NT-proBNP, ST2, neprilysin)",
          "Cardiac regeneration and stem cells",
          "Myocardial tissue engineering",
          "Sudden cardiac death",
          "Precision medicine in heart failure",
          "PAPP-A in ACS (landmark NEJM 2001)"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Francisco Fernández-Avilés",
        "institution": "",
        "city": "Madrid",
        "specialty": [
          "Myocardial regeneration and protection",
          "Cardiac CT and MRI imaging",
          "Arrhythmias and cardiac mapping",
          "Cardiology AI (Corify Care co-founder)",
          "Regenerative medicine"
        ],
        "publications": "",
        "h_index": 42,
        "source": "discovered",
        "score": 82
      },
      {
        "name": "Manel Sabaté",
        "institution": "",
        "city": "Barcelona, Catalonia",
        "specialty": [
          "Interventional cardiology",
          "PCI in complex patients (diabetes, multivessel disease)",
          "Drug-eluting stents and bioresorbable scaffolds",
          "Coronary physiology",
          "SYNTAX trial (10-year follow-up in Lancet)"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Javier Jiménez-Candil",
        "institution": "",
        "city": "Salamanca, Castilla y León",
        "specialty": [
          "Cardiac arrhythmias and electrophysiology",
          "ICD and sudden cardiac death prevention",
          "Ventricular tachycardia ablation",
          "Post-infarction arrhythmia monitoring",
          "Remote monitoring in heart failure arrhythmias"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Juan Sanchis Forés",
        "institution": "",
        "city": "Valencia",
        "specialty": [
          "NSTEMI in elderly and frail patients",
          "Geriatric cardiology",
          "ACS management strategies",
          "Invasive vs. conservative strategy in frailty (MOSCA-FRAIL trial PI)"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Antonio Berruezo Sánchez",
        "institution": "",
        "city": "Barcelona, Catalonia",
        "specialty": [
          "Cardiac electrophysiology",
          "Ventricular tachycardia ablation",
          "Sudden cardiac death prevention",
          "Pacemakers and defibrillators",
          "Arrhythmia mechanisms"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Armando Pérez de Prado",
        "institution": "",
        "city": "León, Castilla y León",
        "specialty": [
          "Interventional cardiology",
          "Preclinical (animal model) research on coronary and structural devices",
          "Left atrial appendage (LAA) and PFO closure",
          "Ethics in clinical research",
          "COVID-19 interventional cardiology impact (ACI-SEC registry)"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Oriol Rodríguez-Leor",
        "institution": "",
        "city": "Badalona (Barcelona metropolitan area), Catalonia",
        "specialty": [
          "Interventional cardiology",
          "Acute coronary syndromes (STEMI / cardiogenic shock)",
          "Intravascular lithotripsy (IVL) — PI REPLICA-EPIC18 registry",
          "COVID-19 interventional cardiology impact",
          "Renal denervation",
          "Intravascular imaging (IVUS)"
        ],
        "publications": "",
        "h_index": 32,
        "source": "discovered",
        "score": 75
      },
      {
        "name": "Pablo Avanzas",
        "institution": "",
        "city": "Oviedo, Asturias",
        "specialty": [
          "Interventional cardiology",
          "Structural heart disease (TAVI, MitraClip, percutaneous valve replacement)",
          "Coronary artery disease and biomarkers",
          "Cardiac syndrome X",
          "Pharmacotherapy in cardiovascular disease"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Domingo Pascual-Figal",
        "institution": "",
        "city": "El Palmar, Murcia",
        "specialty": [
          "Heart failure (biomarkers, congestion, NT-proBNP)",
          "Cardiometabolic disease",
          "Acute heart failure management",
          "Clinical trial design in HF (COLICA trial)",
          "Cardiac biotech / precision diagnostics (patents)"
        ],
        "publications": "",
        "h_index": 64,
        "source": "discovered",
        "score": 82
      },
      {
        "name": "Pedro Luis Sánchez Fernández",
        "institution": "",
        "city": "Salamanca, Castilla y León",
        "specialty": [
          "Structural heart disease (TAVI programme lead)",
          "Cardiac rhythm monitoring",
          "Artificial intelligence in cardiology",
          "Beta-blocker therapy after MI (REBOOT trial — co-investigator)",
          "NT-proBNP monitoring in heart failure"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Pablo García-Pavía",
        "institution": "",
        "city": "Majadahonda, Madrid",
        "specialty": [
          "Inherited cardiomyopathies (dilated, hypertrophic, arrhythmogenic)",
          "Cardiac amyloidosis (transthyretin TTR amyloidosis — global leading expert)",
          "Heart failure with reduced and preserved ejection fraction",
          "Precision medicine / genetics in heart disease",
          "AI in cardiac disease (Idoven Medical Advisor)"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      },
      {
        "name": "Javier Escaned",
        "institution": "",
        "city": "Madrid",
        "specialty": [
          "Coronary physiology (FFR, iFR, instantaneous wave-free ratio)",
          "Intracoronary imaging (OCT, IVUS)",
          "Complex PCI and chronic total occlusion (CTO)",
          "SYNTAX II trial",
          "Spontaneous coronary artery dissection (SCAD)",
          "Microcirculatory dysfunction"
        ],
        "publications": "",
        "h_index": 67,
        "source": "discovered",
        "score": 82
      },
      {
        "name": "Fernando Alfonso",
        "institution": "",
        "city": "Madrid",
        "specialty": [
          "In-stent restenosis (DCB vs. DES — RIBS IV, V, VI trials PI)",
          "Intracoronary imaging (OCT, IVUS)",
          "Spontaneous coronary artery dissection (SCAD — international ESC position paper lead)",
          "Complex PCI",
          "Interventional cardiology quality and outcomes"
        ],
        "publications": "",
        "h_index": 93,
        "source": "discovered",
        "score": 88
      },
      {
        "name": "Carlos Macaya",
        "institution": "",
        "city": "Madrid",
        "specialty": [
          "Interventional cardiology (pioneer in Spain)",
          "Coronary stenting — historical pioneer",
          "SCAD (spontaneous coronary artery dissection)",
          "Polypill / secondary prevention (METOCARD-CNIC, SECURE)",
          "Drug-eluting stents and antithrombotic therapy"
        ],
        "publications": "",
        "h_index": null,
        "source": "discovered",
        "score": 70
      }
    ]
  },
  "publications": [
    {
      "title": "Allogeneic transplantation in advanced cutaneous T-cell lymphomas (CUTALLO): a propensity score matched controlled prospective study",
      "authors": [
        "de Masson A",
        "Beylot-Barry M",
        "Bouaziz J-D",
        "Peffault de Latour R",
        "Aubin F",
        "et al — GFELC & SFGM-TC"
      ],
      "journal": "The Lancet",
      "year": 2023,
      "doi": "10.1016/S0140-6736(23)00329-X"
    },
    {
      "title": "EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome — update 2023",
      "authors": [
        "Bagot M",
        "et al — EORTC Cutaneous Lymphoma Group"
      ],
      "journal": "European Journal of Cancer",
      "year": 2023,
      "doi": "10.1016/j.ejca.2023.113343"
    },
    {
      "title": "Effectiveness of mogamulizumab in patients with Mycosis Fungoides or Sézary syndrome: A multicentre, retrospective, real-world French study (OMEGA study)",
      "authors": [
        "Beylot-Barry M",
        "et al — GFELC"
      ],
      "journal": "Journal of the European Academy of Dermatology and Venereology (JEADV)",
      "year": 2023,
      "doi": "10.1111/jdv.19134"
    },
    {
      "title": "Lacutamab (IPH4102) in relapsed/refractory mycosis fungoides and Sézary syndrome: TELLOMAK phase 2 final results",
      "authors": [
        "Porcu P",
        "Bagot M",
        "et al"
      ],
      "journal": "Journal of Clinical Oncology (ASCO Annual Meeting Suppl)",
      "year": 2024,
      "doi": "10.1200/JCO.2024.42.16_suppl.7082"
    },
    {
      "title": "Pathophysiology of cutaneous T-cell lymphomas: A French perspective",
      "authors": [
        "de Masson A",
        "et al"
      ],
      "journal": "Immunology Letters",
      "year": 2024,
      "doi": "10.1016/j.imlet.2024.106871"
    },
    {
      "title": "Therapeutic advances in cutaneous T-cell lymphomas",
      "authors": [
        "Bagot M"
      ],
      "journal": "British Journal of Dermatology",
      "year": 2025,
      "doi": "10.1093/bjd/ljaf105"
    },
    {
      "title": "Cutaneous T-Cell Lymphoma and Dupilumab Use: A Multifactorial Challenge",
      "authors": [
        "Beylot-Barry M",
        "Staumont-Sallé D"
      ],
      "journal": "Journal of Investigative Dermatology",
      "year": 2025,
      "doi": "10.1016/j.jid.2024.08.015"
    },
    {
      "title": "Treatment patterns and outcomes in patients with relapsed/refractory mycosis fungoides in five European countries",
      "authors": [
        "Bagot M",
        "et al"
      ],
      "journal": "Cancers",
      "year": 2023,
      "doi": "10.3390/cancers15235669"
    },
    {
      "title": "Phase 2 study of mogamulizumab every 4 weeks (Q4W) in advanced cutaneous T-cell lymphoma",
      "authors": [
        "Bagot M",
        "et al"
      ],
      "journal": "Blood (ASH Annual Meeting Abstracts)",
      "year": 2024,
      "doi": "10.1182/blood-2024-200596"
    },
    {
      "title": "Overall survival after allogeneic hematopoietic stem cell transplantation for cutaneous T-cell lymphoma — long-term follow-up of the CUTALLO trial",
      "authors": [
        "Bouaziz J-D",
        "de Masson A",
        "Bagot M",
        "et al — GFELC & SFGM-TC"
      ],
      "journal": "Journal of Clinical Oncology",
      "year": 2025,
      "doi": "10.1200/JCO-25-00183"
    },
    {
      "title": "Rethinking prognostic boundaries in early-stage mycosis fungoides",
      "authors": [
        "de Masson A",
        "et al — Saint-Louis team"
      ],
      "journal": "PMID:41431959",
      "year": 2026,
      "doi": null
    },
    {
      "title": "Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French Cutaneous Lymphoma Registry",
      "authors": [
        "GFELC Registry authors"
      ],
      "journal": "British Journal of Dermatology",
      "year": 2021,
      "doi": null
    },
    {
      "title": "Real-life efficacy of immunotherapy for Sézary syndrome",
      "authors": [
        "Aubin F",
        "et al"
      ],
      "journal": "eClinicalMedicine (The Lancet)",
      "year": 2024,
      "doi": "10.1016/j.eclinm.2024.102581"
    }
  ],
  "treatments": {
    "standard_of_care_by_stage": {
      "stage_IA_IB_early": {
        "description": "MF stades IA-IB (plaques limitées ou étendues, sans atteinte ganglionnaire ni sanguine significative)",
        "therapies": [
          {
            "name": "Dermocorticoïdes (topiques forts)",
            "type": "Traitement local",
            "indication": "Lésions localisées IA; traitement de première intention",
            "approval_status": "Standard of care France",
            "brand_name": null
          },
          {
            "name": "Chlorméthine gel",
            "generic_name": "Méchloréthamine",
            "brand_name": "Ledaga® 160 µg/g",
            "type": "Alkylant topique",
            "indication": "MF stades IA-IIA",
            "approval_status": "AMM EMA (approbation 2017, SPC 2024 actualisé)",
            "manufacturer": "Recordati Rare Diseases (Orphan Europe)",
            "url": "https://ec.europa.eu/health/documents/community-register/2024/20240916163942/anx_163942_fr.pdf"
          },
          {
            "name": "Photothérapie UVB TL01 (bande étroite)",
            "type": "Photothérapie",
            "indication": "MF stades IA-IIA, plaques",
            "approval_status": "Standard of care France"
          },
          {
            "name": "PUVAthérapie (psoralène + UVA)",
            "type": "Photothérapie",
            "indication": "MF stades IIA-IIB; plaques épaisses",
            "approval_status": "Standard of care France"
          },
          {
            "name": "Radiothérapie localisée",
            "type": "Radiothérapie",
            "indication": "Lésions localisées tumorales IIB; patches résistants",
            "approval_status": "Standard of care France"
          }
        ]
      },
      "stage_IIA_IIB_intermediate": {
        "description": "MF stades IIA (ganglions palpables N1 non atteints) à IIB (tumeurs cutanées)",
        "therapies": [
          {
            "name": "Interféron alpha pégylé",
            "generic_name": "Peginterféron alfa-2a / alfa-2b",
            "brand_name": "Pegasys® / PegIntron®",
            "type": "Immunomodulateur",
            "indication": "MF IB-IIA-IIB systémique",
            "approval_status": "Hors AMM CTCL mais recommandé EORTC 2023 (remplacement de l'IFN standard)",
            "note": "L'IFN pégylé a remplacé progressivement l'IFN alpha standard selon mise à jour EORTC 2023"
          },
          {
            "name": "Méthotrexate",
            "type": "Immunosuppresseur / antiprolifératif",
            "indication": "MF plaques récalcitrantes; MF folliculotrope",
            "approval_status": "Hors AMM CTCL mais standard clinique"
          },
          {
            "name": "Bexarotène",
            "brand_name": "Targretin® 75 mg",
            "type": "Rétinoïde de 3e génération (RXR agoniste)",
            "indication": "MF stades IB à IVB réfractaire",
            "approval_status": "AMM Europe pour MF stades IB-IVB après échec au moins 1 traitement systémique",
            "manufacturer": "Eisai"
          },
          {
            "name": "Photochimiothérapie extracorporelle (ECP)",
            "type": "Immunothérapie extracorporelle",
            "indication": "MF stades avancés avec composante sanguine; SS",
            "approval_status": "Disponible dans certains centres GFELC; remboursé pour SS France"
          }
        ]
      },
      "stage_III_SS_blood_advanced": {
        "description": "MF stade III-IV ou Syndrome de Sézary (cellules tumorales circulantes B2)",
        "therapies": [
          {
            "name": "Mogamulizumab",
            "brand_name": "Poteligeo®",
            "generic_name": "Mogamulizumab",
            "type": "Anticorps monoclonal anti-CCR4 (IgG1 afucosylé)",
            "indication": "MF/SS après au moins 1 traitement systémique antérieur",
            "approval_status": "AMM EMA 2018; Remboursé en France (liste en sus hôpital)",
            "manufacturer": "Kyowa Kirin",
            "mechanism": "Déplétion cellules T régulatrices CCR4+; ADCC amélioré",
            "key_data": "MAVORIC Ph3 (IFO vs vorinostat); ORR 28% MF, 37% SS; PFS 7.7 vs 3.1 mois; vie réelle France OMEGA: ORR 58.7%",
            "administration": "IV toutes les 2 semaines (Q2W) × 4 puis Q4W; optimisation Q4W en évaluation"
          },
          {
            "name": "Brentuximab védotine",
            "brand_name": "Adcetris®",
            "generic_name": "Brentuximab védotine",
            "type": "Anticorps-drogue conjugué (ADC) anti-CD30",
            "indication": "MF CD30+ (≥10%) après au moins 1 traitement systémique antérieur",
            "approval_status": "AMM EMA 2017 pour MF CD30+; remboursé France (liste en sus)",
            "manufacturer": "Takeda / Seagen",
            "mechanism": "Anti-CD30 conjugué à MMAE (auristatine E); ALCANZA Ph3",
            "key_data": "ALCANZA: ORR 56.3% vs 12.5%; PFS 16.7 vs 3.5 mois dans MF CD30+"
          },
          {
            "name": "Photochimiothérapie extracorporelle (ECP)",
            "type": "Immunothérapie extracorporelle",
            "indication": "SS et MF stades avancés avec atteinte sanguine",
            "approval_status": "Remboursé France pour SS; centres équipés GFELC"
          }
        ]
      },
      "potentially_curative_advanced": {
        "description": "Traitement potentiellement curatif pour CTCL avancé",
        "therapies": [
          {
            "name": "Greffe allogénique de cellules souches hématopoïétiques (HSCT)",
            "type": "Greffe allogénique",
            "indication": "CTCL avancé (MF stade IIB-IV, SS); patients éligibles à la greffe avec donneur compatible",
            "approval_status": "Recommandé EORTC 2023 pour patients éligibles à la greffe en CTCL avancé; seul traitement potentiellement curatif",
            "key_evidence": "CUTALLO trial (Lancet 2023): HR OS 0.37 (p=0.018); amélioration survie sans progression confirmée",
            "centres_GFELC": "Saint-Louis (référent), Bordeaux, Lyon, Lille, Nantes, Tours, Rennes, Montpellier, autres centres GFELC"
          }
        ]
      }
    },
    "emerging_therapies": [
      {
        "name": "Lacutamab",
        "code": "IPH4102",
        "target": "KIR3DL2 (CD158k)",
        "type": "Anticorps monoclonal anti-KIR3DL2",
        "developer": "Innate Pharma (Marseille, France — cotée Euronext, Nasdaq)",
        "stage": "Phase 3 (TELLOMAK 3) en cours de démarrage H1 2026",
        "indication": "SS R/R et MF R/R (SS en priorité)",
        "regulatory_status": "FDA Breakthrough Therapy Designation (SS); EMA PRIME designation",
        "key_data": "TELLOMAK Ph2: ORR 42.9% SS; durée de réponse durable; bonne tolérance",
        "french_connection": "Développé par Innate Pharma Marseille; centres GFELC co-investigateurs; Bensussan/Saint-Louis identifiants originaux KIR3DL2",
        "urls": [
          "https://www.innate-pharma.com/media/all-press-releases/innate-pharma-announces-fda-clearance-proceed-tellomak-3-confirmatory-phase-3-trial-lacutamab-ctcl"
        ],
        "timeline": "TELLOMAK 3 FDA IND cleared 2025; Phase 3 démarrage H1 2026"
      },
      {
        "name": "Anti-CCR8 mAb (projet SPRINT)",
        "target": "CCR8 (C-C Chemokine Receptor 8)",
        "type": "Anticorps monoclonal anti-CCR8",
        "developer": "Équipe de Masson — INSERM U976 / Saint-Louis; financement ANR",
        "stage": "Préclinique / Découverte (ANR-financé)",
        "indication": "CTCL (MF/SS)",
        "key_data": "CCR8 surexprimé dans les T-reg tumoraux CTCL; ciblage sélectif T-reg tumoraux sans affecter T effecteurs. Article The Conversation Aug 2025.",
        "french_connection": "Projet 100% français; ANR; équipe Saint-Louis de Masson",
        "urls": [
          "https://theconversation.com/lymphomes-t-cutanes-ces-cancers-de-la-peau-meconnus-mais-en-augmentation-262455"
        ]
      },
      {
        "name": "CAR-T CTCL",
        "target": "CD4, CD7, CD30 (divers)",
        "type": "Thérapie cellulaire CAR-T",
        "stage": "Essais de phase 1-2 (non France-spécifique mais centres GFELC participants)",
        "indication": "CTCL avancé R/R",
        "key_data": "Entrée en essais cliniques CTCL 2024-2025; débat sur efficacité vs toxicité auto-immune dans T-cell malignancy",
        "notes": "Mentionne par Bagot BJD 2025 comme thérapie émergente"
      },
      {
        "name": "Romidepsine",
        "type": "Inhibiteur d'histone désacétylase (HDACi)",
        "stage": "Approuvé FDA 2009 (non AMM EMA — non disponible commercialement en France)",
        "indication": "CTCL R/R",
        "notes": "Disponible en accès compassionnel ou essai clinique en France; réponse dans MF/SS R/R"
      },
      {
        "name": "Mogamulizumab + Total Skin Electron Beam (TSEB) — MOGAT trial",
        "type": "Combinaison immunothérapie + radiothérapie",
        "trial_id": "NCT04128072 / EORTC-1820-CLTF",
        "stage": "Phase 2 en cours",
        "indication": "MF stades IB-IIB réfractaire à au moins 1 traitement systémique",
        "centres_France": [
          "Bordeaux",
          "Paris"
        ],
        "url": "https://clinicaltrials.gov/study/NCT04128072",
        "notes": "Mogamulizumab avant TSEB pour contrôle sanguin, puis maintenance. Centres GFELC participants."
      }
    ],
    "clinical_trials_france": [
      {
        "trial_name": "CUTALLO",
        "nct_id": "NCT02520908",
        "phase": "Prospectif contrôlé (non randomisé — appariement propensity score)",
        "status": "Terminé — publié Lancet 2023",
        "sponsor": "INCa (PHRC-K 2014) / GFELC / SFGM-TC",
        "primary_endpoint": "Survie sans progression",
        "result": "Positif — HR OS 0.37 (p=0.018); recommandation EORTC 2023"
      },
      {
        "trial_name": "MOGAT (mogamulizumab + TSEB)",
        "nct_id": "NCT04128072",
        "protocol_id": "EORTC-1820-CLTF",
        "phase": "Phase 2",
        "status": "En cours (ouvert aux inclusions)",
        "indication": "MF stades IB-IIB",
        "centres_France": [
          "Bordeaux (CHU Haut-Lévêque)",
          "Paris (Hôpital Saint-Louis)"
        ],
        "url": "https://clinicaltrials.gov/study/NCT04128072"
      },
      {
        "trial_name": "TELLOMAK 3 (lacutamab confirmatory Phase 3)",
        "phase": "Phase 3 confirmatory",
        "status": "Démarrage H1 2026 (FDA IND cleared 2025)",
        "sponsor": "Innate Pharma (Marseille)",
        "indication": "SS et MF R/R",
        "regulatory_designation": "FDA Breakthrough Therapy (SS); EMA PRIME",
        "url": "https://www.innate-pharma.com/media/all-press-releases/innate-pharma-announces-fda-clearance-proceed-tellomak-3-confirmatory-phase-3-trial-lacutamab-ctcl"
      },
      {
        "trial_name": "Transplantation After Complete Response in T-cell Lymphoma",
        "nct_id": "NCT05444712",
        "phase": "Phase N/A (interventionnel)",
        "status": "En recrutement (Île-de-France; sponsor HCL Lyon)",
        "indication": "Lymphomes T (incluant MF/SS CTCL après RC)",
        "url": "https://essaisclic.girci-idf.fr/EssaiClinique/Detail/Essai/NCT05444712"
      }
    ]
  },
  "trending_topics": [
    {
      "topic": "Lacutamab / KIR3DL2 — Phase 3 imminente (TELLOMAK 3)",
      "priority": "TRÈS HAUTE",
      "description": "La Phase 3 confirmatory (TELLOMAK 3) de lacutamab (IPH4102, Innate Pharma Marseille) dans le SS/MF R/R va démarrer H1 2026. FDA Breakthrough Therapy Designation (SS) + EMA PRIME. Premier anticorps ciblant KIR3DL2, identifié par l'équipe Bensussan/Saint-Louis. ORR 42.9% SS en Phase 2."
    },
    {
      "topic": "Dupilumab et risque de CTCL — Controverse majeure 2024-2025",
      "priority": "TRÈS HAUTE",
      "description": "Le dupilumab (Dupixent®, Sanofi/Regeneron), blockbuster de la dermatite atopique, est associé à un risque de 'démasquage' ou d'aggravation d'un MF préexistant. L'éditorial GFELC (Beylot-Barry & Staumont-Sallé, JID 2025) alerte sur l'importance du diagnostic différentiel DA vs MF précoce avant initiation. Réel impact pratique: combien de patients DA traités par dupilumab ont en réalité un MF précoce?"
    },
    {
      "topic": "CUTALLO trial — établissement de l'HSCT allogénique comme nouveau standard",
      "priority": "HAUTE",
      "description": "L'essai CUTALLO (Lancet 2023) a définitivement établi que la greffe allogénique améliore significativement la survie dans le CTCL avancé. Les données long terme (JCO 2025) confirment le bénéfice de survie globale. Nouvelle recommandation intégrée dans les guidelines EORTC 2023."
    },
    {
      "topic": "CCR8 comme nouvelle cible thérapeutique — Projet SPRINT",
      "priority": "HAUTE",
      "description": "L'équipe de Masson/INSERM U976 (Saint-Louis) a identifié CCR8 comme cible prometteuse dans le CTCL, exprimé sélectivement par les T-reg tumoraux. Un anticorps anti-CCR8 en développement (projet ANR SPRINT) pourrait cibler les cellules tumorales sans affecter l'immunité anti-tumorale. Article The Conversation août 2025 pour le grand public."
    },
    {
      "topic": "Session JDP 2025 — 'Traitement des LTC : où en sommes-nous en 2025?'",
      "priority": "HAUTE",
      "description": "Session LTC dédiée aux JDP 2025 (Journées Dermatologiques de Paris, décembre 2025), coordinateur Pr Florent Grange (Reims), orateurs: Pr Gaëlle Quéreux (Nantes), Dr Yannick Le Corre (Angers). Jury poster LTC: Pr Alain Dupuy (Rennes). État de l'art national 2025."
    },
    {
      "topic": "EADV Cutaneous Lymphoma Course 2025 — Bordeaux",
      "priority": "HAUTE",
      "description": "Cours dédié lymphomes cutanés EADV, organisé à Bordeaux en février 2025, co-présidé par Pr Marie Beylot-Barry. Programme complet lymphomes cutanés: sessions diagnostiques, thérapeutiques, cas cliniques. Formation phare européenne."
    },
    {
      "topic": "Gestion du rash au mogamulizumab (mogamulizumab-associated rash)",
      "priority": "MOYENNE-HAUTE",
      "description": "La gestion du rash cutané induit par mogamulizumab (MAR) est un défi clinique majeur: distinguer la toxicité cutanée du mogamulizumab d'une progression du CTCL. Session dédiée à l'EADV 2025 par Dr Florent Amatore (Marseille). Impact sur la décision de maintien du traitement."
    },
    {
      "topic": "Intelligence artificielle dans le diagnostic des lymphomes cutanés",
      "priority": "MOYENNE",
      "description": "Développement d'algorithmes d'IA pour aide au diagnostic dermoscopique et anatomopathologique des CTCL. Publication 2025 (Diagnostics 15:1089). Enjeux: accès précoce au diagnostic dans les centres non experts."
    },
    {
      "topic": "IFN pégylé — remplacement de l'IFN standard (recommandation EORTC 2023)",
      "priority": "MOYENNE",
      "description": "Les recommandations EORTC 2023 ont officialisé le remplacement de l'interféron alpha classique par l'interféron pégylé dans le traitement systémique du MF. Meilleure tolérance, administration hebdomadaire vs trihebdomadaire."
    },
    {
      "topic": "Registre GFELC et données épidémiologiques nationales",
      "priority": "MOYENNE",
      "description": "Le registre GFELC (8593 patients, BJD 2021) fournit les données épidémiologiques nationales de référence. Mise à jour continue. Incidence en augmentation sur 20 ans: environ 0.5-1/100 000 habitants/an en France."
    }
  ],
  "gfelc": {
    "description": "Groupe Français d'Etude des Lymphomes Cutanés (GFELC) — réseau national de 47 centres (français + francophones)",
    "national_chair": "Pr Martine Bagot (Hôpital Saint-Louis, Paris)",
    "website": "https://www.gfelc.org",
    "centres_reference_url": "https://www.gfelc.org/centres-de-reference/",
    "inca_list_url": "https://www.cancer.fr/Media/files/responsables-centres-experts-des-lymphomes-cutanes",
    "centres_france": [
      {
        "city": "Paris",
        "hospital": "AP-HP Hôpital Saint-Louis",
        "region": "Île-de-France",
        "type": "Centre national de référence",
        "key_physicians": [
          "Pr Martine Bagot",
          "Pr Jean-David Bouaziz",
          "Dr Adèle de Masson",
          "Dr Maxime Battistella",
          "Dr Caroline Ram-Wolff",
          "Pr Armand Bensussan",
          "Dr Hélène Moins-Teisserenc"
        ]
      },
      {
        "city": "Paris",
        "hospital": "AP-HP Hôpital Bichat",
        "region": "Île-de-France",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Eve Maubec"
        ]
      },
      {
        "city": "Paris",
        "hospital": "AP-HP Hôpital Cochin / Tarnier",
        "region": "Île-de-France",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Nathalie Franck"
        ]
      },
      {
        "city": "Bobigny",
        "hospital": "AP-HP Hôpital Avicenne",
        "region": "Île-de-France",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Eve Maubec",
          "Pr Liliane Laroche"
        ]
      },
      {
        "city": "Créteil",
        "hospital": "AP-HP Hôpital Henri Mondor",
        "region": "Île-de-France",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Saskia Ingen-Housz-Oro"
        ]
      },
      {
        "city": "Paris",
        "hospital": "AP-HP Hôpital Ambroise-Paré",
        "region": "Île-de-France",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Paris",
        "hospital": "AP-HP Hôpital Pitié / Tenon",
        "region": "Île-de-France",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Bordeaux",
        "hospital": "CHU Hôpital Haut-Lévêque",
        "region": "Nouvelle-Aquitaine",
        "type": "Centre expert régional majeur",
        "key_physicians": [
          "Pr Marie Beylot-Barry",
          "Pr Anne Pham-Ledard",
          "Pr Béatrice Vergier",
          "Dr Jean-Philippe Merlio",
          "Dr Audrey Gros",
          "Dr Fanny Beltzung"
        ],
        "research_unit": "INSERM U1312 (BRIC)"
      },
      {
        "city": "Lyon",
        "hospital": "CHU Hôpital Lyon Sud",
        "region": "Auvergne-Rhône-Alpes",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Stéphane Dalle"
        ]
      },
      {
        "city": "Lyon",
        "hospital": "Centre Léon Bérard",
        "region": "Auvergne-Rhône-Alpes",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Patrick Combemale"
        ]
      },
      {
        "city": "Montpellier",
        "hospital": "CHU Hôpital Saint-Éloi",
        "region": "Occitanie",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Olivier Dereure"
        ],
        "research_unit": "INSERM U1058"
      },
      {
        "city": "Toulouse",
        "hospital": "CHU Hôpital La Grave",
        "region": "Occitanie",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Roland Viraben"
        ]
      },
      {
        "city": "Marseille",
        "hospital": "AP-HM Hôpital Nord",
        "region": "PACA",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Philippe Berbis",
          "Dr Florent Amatore"
        ]
      },
      {
        "city": "Marseille",
        "hospital": "Institut Paoli-Calmettes",
        "region": "PACA",
        "type": "Centre expert onco-hématologie",
        "key_physicians": [
          "Dr Reda Bouabdallah"
        ]
      },
      {
        "city": "Nice",
        "hospital": "CHU Hôpital de l'Archet",
        "region": "PACA",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Jean-Philippe Lacour"
        ]
      },
      {
        "city": "Nantes",
        "hospital": "CHU Hôtel Dieu",
        "region": "Pays de la Loire",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Gaëlle Quéreux-Baumgartner"
        ]
      },
      {
        "city": "Angers",
        "hospital": "CHU Angers",
        "region": "Pays de la Loire",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Yannick Le Corre"
        ]
      },
      {
        "city": "Rennes",
        "hospital": "CHU Hôpital Pontchaillou",
        "region": "Bretagne",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Alain Dupuy"
        ]
      },
      {
        "city": "Lille",
        "hospital": "CHRU Hôpital Claude Huriez",
        "region": "Hauts-de-France",
        "type": "Centre expert labellisé EURACAN",
        "key_physicians": [
          "Pr Laurent Mortier",
          "Pr Diala Staumont-Sallé"
        ],
        "research_unit": "INSERM U1286 (INFINITE)"
      },
      {
        "city": "Amiens",
        "hospital": "CHU Hôpital Sud",
        "region": "Hauts-de-France",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Catherine Lok"
        ]
      },
      {
        "city": "Reims",
        "hospital": "CHU Hôpital Robert Debré",
        "region": "Grand Est",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Florent Grange"
        ]
      },
      {
        "city": "Strasbourg",
        "hospital": "CHU Clinique dermatologique",
        "region": "Grand Est",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Mona Mitcov"
        ]
      },
      {
        "city": "Mulhouse",
        "hospital": "CH Hôpital Emile Muller",
        "region": "Grand Est",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Catherine Michel"
        ]
      },
      {
        "city": "Besançon",
        "hospital": "CHRU Hôpital Jean Minjoz",
        "region": "Bourgogne-Franche-Comté",
        "type": "Centre expert",
        "key_physicians": [
          "Pr François Aubin"
        ]
      },
      {
        "city": "Dijon",
        "hospital": "CHU Hôpital du Bocage",
        "region": "Bourgogne-Franche-Comté",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Sophie Dalac-Rat"
        ]
      },
      {
        "city": "Rouen",
        "hospital": "CHU Hôpital Charles Nicolle",
        "region": "Normandie",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Pascal Joly",
          "Dr Anne-Bénédicte Duval-Modeste"
        ],
        "research_unit": "INSERM U1234"
      },
      {
        "city": "Caen",
        "hospital": "CHU Caen",
        "region": "Normandie",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Anne Dompmartin"
        ]
      },
      {
        "city": "Tours",
        "hospital": "CHRU Hôpital Trousseau",
        "region": "Centre-Val de Loire",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Laurent Machet"
        ]
      },
      {
        "city": "Orléans",
        "hospital": "CHR Hôpital Porte-Madeleine",
        "region": "Centre-Val de Loire",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Eric Estève"
        ]
      },
      {
        "city": "Poitiers",
        "hospital": "CHU de Poitiers",
        "region": "Nouvelle-Aquitaine",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Ewa Wierzbicka-Hainaut"
        ]
      },
      {
        "city": "Grenoble",
        "hospital": "CHU Hôpital Albert Michallon",
        "region": "Auvergne-Rhône-Alpes",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Isabelle Templier"
        ]
      },
      {
        "city": "Clermont-Ferrand",
        "hospital": "CHU Hôpital d'Estaing",
        "region": "Auvergne-Rhône-Alpes",
        "type": "Centre expert",
        "key_physicians": [
          "Pr Michel d'Incan"
        ]
      },
      {
        "city": "Nancy",
        "hospital": "CHU Nancy",
        "region": "Grand Est",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Nîmes",
        "hospital": "CHU Nîmes",
        "region": "Occitanie",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Annecy",
        "hospital": "CH Annecy-Genevois",
        "region": "Auvergne-Rhône-Alpes",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Metz-Thionville",
        "hospital": "CH Metz-Thionville",
        "region": "Grand Est",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Valence",
        "hospital": "CH Valence",
        "region": "Auvergne-Rhône-Alpes",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Blois",
        "hospital": "CH Blois",
        "region": "Centre-Val de Loire",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Colmar",
        "hospital": "CH Colmar",
        "region": "Grand Est",
        "type": "Centre expert",
        "key_physicians": []
      },
      {
        "city": "Pointe-à-Pitre",
        "hospital": "CHU Hôpital Abymes",
        "region": "Guadeloupe (DOM)",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Nadège Cordel"
        ]
      },
      {
        "city": "Fort-de-France",
        "hospital": "CHU Hôpital Pierre Zobda Quitman",
        "region": "Martinique (DOM)",
        "type": "Centre expert",
        "key_physicians": [
          "Dr Christian Derancourt"
        ]
      }
    ],
    "centres_francophones": [
      {
        "city": "Bruxelles",
        "country": "Belgique",
        "hospital": "ULB Hôpital Erasme"
      },
      {
        "city": "Louvain",
        "country": "Belgique",
        "hospital": "UCLouvain Cliniques universitaires Saint-Luc"
      },
      {
        "city": "Charleroi",
        "country": "Belgique",
        "hospital": "CHU de Charleroi"
      },
      {
        "city": "Genève",
        "country": "Suisse",
        "hospital": "HUG Hôpitaux Universitaires Genève"
      },
      {
        "city": "Lausanne",
        "country": "Suisse",
        "hospital": "CHUV Lausanne"
      },
      {
        "city": "Berne",
        "country": "Suisse",
        "hospital": "Inselspital Bern"
      },
      {
        "city": "Lugano",
        "country": "Suisse",
        "hospital": "EOC Lugano"
      },
      {
        "city": "Québec",
        "country": "Canada",
        "hospital": "CHUL / CHUQ Québec City"
      }
    ]
  }
};